 VICTORIA, British Columbia CASTRES, France--BUSINESS WIRE--- IPA Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. the Company or IPA NASDAQ: IPA TSX VENTURE: IPA and the Pierre Fabre pharmaceutical group announced today that IPAs subsidiary, Talem Therapeutics LLC Talem, and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets. This strategic collaboration is expected to help expand Talems por 